Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
59 60 Next >
3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition
These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation. 
Via InvestorPlace
ABBV Stock: Buy for the Yield, Hold for This Other Reason
"Safe harbor" status and a high, growing dividend yield isn't the only thing that's appealing with ABBV stock. 
Via InvestorPlace
AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
From AstraZeneca
Via Business Wire
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
From AstraZeneca
Via Business Wire
AstraZeneca Unusual Options Activity For September 28
Via Benzinga
Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity
From AstraZeneca Foundation
Via Business Wire
2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague
Two Nasdaq 100 components stand out as plain-as-day values, while another widely owned Nasdaq 100 stock may find it impossible to meet investors' lofty growth expectations. 
Via The Motley Fool
Why Shares of Conduit Pharmaceuticals Are Jumping Wednesday
The stock had a brief big rebound from a huge drop on Tuesday. 
Via The Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive... 
Via Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
AstraZeneca Plc (NASDAQ: AZN) has  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices. 
Via Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
Via Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation 
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.  More than a million people worldwide succumb to infections caused... 
Via Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE 
Via Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday
Goldman Sachs increased the price target for Constellation Brands, Inc. (NYSE: STZ) from $275 to $305. Goldman Sachs analyst Bonnie Herzog maintained a Buy rating. Constellation shares fell 0.8% to... 
Via Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
3 Magnificent Growth Stocks to Buy Right Now
If you're looking for growth, these stocks could be just the ticket. 
Via The Motley Fool
AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo
The companies are still testing to see if their drug has a benefit on overall survival. 
Via Investor's Business Daily
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
Via Benzinga
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
From AstraZeneca
Via Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.